logo
chiral 2025 march event

Chiral Accelerates Drug Discovery Research with Cloud Computing, Hosting a Digital Drug Discovery Seminar on March 27, 2025

  • Author: Chiral Bot
  • Published On: March 11, 2025
  • Category: Events

In this lecture, you will learn about the latest initiatives in digital drug discovery from the perspectives of the roles of the ecosystem, including digital drug discovery research, application development, computational resource infrastructure provision, and industrialization, as a consortium.

Chiral Inc. will introduce examples, including new services that meet the needs of researchers from various backgrounds.

Through the Chiral SaaS Ember platform, Chiral Inc. has already been providing drug discovery applications such as myPresto5™. In this lecture and discussion, we will introduce two new products, Potter and Silva, in addition to Chiral SaaS.

Potter is a product aimed at a broader user base, enabling the creation of workflows across multiple applications without coding.

Silva is a tool developed for users already familiar with terminal tools. It allows users to leverage existing scripts and extend processes such as computational resource allocation.

In the discussion, not only drug discovery researchers but also drug discovery application development researchers will be invited to gain an overview of the history, challenges, and future development of digital drug discovery.

During the discussion, participants will be able to post questions through an online system, and the speakers will provide answers. We look forward to your active participation.

To participate in this lecture and discussion, please register via the provided link. Peatix Link

Event Overview

  • HostChiral Inc.
  • CollaboratorsJapan Bioindustry Consortium (JBIC) ・ Fukuoka Growth Next ・ Sakura Internet Inc.
  • Date and TimeThursday, March 27, 2025, 15:00–17:00 (Doors open: 14:45)
  • VenueSakura Internet Inc. Tokyo Office

Schedule

  • 15:00Keynote Speech (30 minutes)
    Hideki Yamaguchi (Group Manager, Machine Learning Group, Modality Research Department, Research Headquarters, Chugai Pharmaceutical Co., Ltd.)
  • 15:30Lecture (10 minutes)
    Improving Computational Performance and User Experience through GPU Server Optimization: A Case Study of myPresto Cloud Edition
    Qin Wang (CEO, Chiral Inc.)
  • 15:40Lecture (10 minutes)
    GPU Cloud Services Provided by Sakura Internet (Tentative Title)
    Taro Odashima (Development Manager, Business Development Department, Cloud Business Division, Sakura Internet Inc.)
  • 15:50Lecture (10 minutes)
    Introduction to JBIC (Japan Bioindustry Consortium) Activities and Research Development Outcomes
    JBIC Representative
  • 16:00Discussion (30 minutes)
    Digital Drug Discovery Accelerated by GPUs
    Hideki Yamaguchi (Chugai Pharmaceutical Co., Ltd.)
    Yoshifumi Fukunishi (National Institute of Advanced Industrial Science and Technology)
    Toshikazu Sumi (Cloud Business Division, Sakura Internet Inc.)
    Koji Umeda (Director, Chiral Inc.)
  • 16:30Networking
  • 17:00End

About the Organizations

Japan Bioindustry Consortium (JBIC)

The Japan Bioindustry Consortium (JBIC) conducts research and development of fundamental technologies in the health and medical fields through industry-academia-government collaboration and disseminates the results widely to industries such as pharmaceuticals and IT, as well as academia. JBIC promotes cutting-edge research and development, from foundational research to practical applications, to create innovative pharmaceuticals, medical devices, and utilize ICT in the health and medical fields. It also supports the smooth transition of these results to the industry. To strengthen Japan's drug discovery infrastructure and improve the efficiency of drug discovery research, JBIC conducts surveys and planning activities based on the needs of its member companies, focusing on the latest technological trends and new industry-academia-government collaboration initiatives and projects domestically and internationally.

myPresto5™

myPresto5™ is an open-source molecular computation software for drug discovery support, developed by the Japan Bioindustry Consortium (JBIC) with support from the Japan Agency for Medical Research and Development (AMED), JBIC membership fees, and voluntary activities of developers. For more details, please visit https://www.mypresto5.jp/.

Chiral Inc.

Chiral Inc. provides backend functionality as SaaS to enable cloud computing for software in fields such as life sciences and drug discovery, which require extensive computational processing.

Address2-6-11 Daimyo, Chuo-ku, Fukuoka City, Fukuoka Prefecture, Fukuoka Growth Next
CEOQin Wang
EstablishedMay 2021
Websitehttps://www.chiral.one

Contact Information for This Press Release


Chiral Inc.
Public Relations: Koji Umeda
TEL: 050-5539-4886
E-Mail: info@chiral.one

  • Share: